{"id":2863,"date":"2026-09-03T07:00:00","date_gmt":"2026-09-03T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2863"},"modified":"2026-09-04T16:45:29","modified_gmt":"2026-09-04T20:45:29","slug":"ivonescimab-meets-harmoni-2-overall-survival-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2863","title":{"rendered":"Ivonescimab Meets HARMONi-2 Overall-Survival Endpoint"},"content":{"rendered":"

Companies:<\/strong> Akeso \/ Summit Therapeutics · Drug:<\/strong> Ivonescimab · Trial:<\/strong> HARMONi-2 (AK112-303, Phase III) · Indication:<\/strong> First-Line PD-L1-Positive Advanced NSCLC · Date:<\/strong> September 3, 2026<\/p>\n

\"Ivonescimab<\/p>\n

Summary<\/h4>\n

Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind Phase III study in 398 patients with PD-L1-positive advanced non-small-cell lung cancer in China. The prespecified interim analysis met the key secondary endpoint, extending the earlier progression-free-survival result. No survival hazard ratio, medians, confidence interval, maturity, subgroup data or updated safety table has been disclosed.<\/p>\n

What Happened<\/h4>\n

HARMONi-2, also designated AK112-303, compared ivonescimab with pembrolizumab as monotherapy in previously untreated, locally advanced or metastatic NSCLC with PD-L1 tumor-proportion score of at least 1%. Akeso’s September 3 Hong Kong filing confirmed a statistically significant and company-characterized clinically meaningful OS advantage at the planned interim analysis. Detailed results are reserved for a future medical meeting or publication. Earlier reporting showed median PFS of 11.14 months with ivonescimab versus 5.82 months with pembrolizumab, hazard ratio 0.51 and p<0.0001. China’s regulator approved ivonescimab for this setting in April 2025. The new OS result strengthens that China-based package, but it is not a regulatory decision in the United States or Europe and does not validate Summit’s ongoing global HARMONi-7 study.<\/p>\n

Deep Analysis<\/h4>\n

Ivonescimab combines PD-1 blockade with VEGF sequestration in one tetravalent antibody. The design could intensify checkpoint activity within a VEGF-rich tumor microenvironment while limiting systemic VEGF exposure, but clinical contribution of each mechanism cannot be separated in this active-control trial. OS is less vulnerable than PFS to imaging-assessment bias, although post-progression therapy and regional treatment patterns can still influence the result. A robust OS hazard ratio with mature follow-up, consistent benefit across PD-L1 strata and no offsetting fatal-toxicity signal would support genuine superiority over pembrolizumab in the studied population, and the positive PFS and now positive OS sequence is directionally coherent, though the missing effect size and maturity prevent assessment of magnitude, proportionality and durability. The finding may also be valid in HARMONi-2 yet translate incompletely to global practice because enrollment, subsequent therapy, histology mix, smoking history and biomarker distribution may differ; global randomized replication is the decisive test.<\/p>\n

Company and Product Background<\/h4>\n

Akeso originated ivonescimab, also called AK112 or SMT112, and retains rights in Greater China; Summit holds rights in the United States, Canada, Europe, Japan and other territories. Ivonescimab is a tetravalent bispecific antibody designed to block PD-1 and bind VEGF, potentially concentrating both functions in the tumor microenvironment. Advanced NSCLC remains a major cause of cancer mortality. Pembrolizumab is an established first-line checkpoint inhibitor across PD-L1-defined populations, alone or with chemotherapy. Displacement therefore requires survival benefit, tolerable immune and anti-angiogenic toxicity, reproducibility across regions and clarity about which PD-L1 and genomic subgroups benefit.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial<\/td>\nHARMONi-2 (AK112-303), 398 patients, randomized double-blind Phase III<\/td>\n<\/tr>\n
Comparator<\/td>\nPembrolizumab monotherapy, first-line PD-L1 TPS ≥1% NSCLC<\/td>\n<\/tr>\n
Result<\/td>\nPrespecified interim OS endpoint met (statistically significant); no HR\/medians disclosed<\/td>\n<\/tr>\n
Prior PFS Data<\/td>\n11.14 vs. 5.82 months; HR 0.51; p<0.0001<\/td>\n<\/tr>\n
Regulatory Context<\/td>\nChina approved this setting April 2025; not a US\/EU decision; global HARMONi-7 ongoing<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A prespecified overall-survival endpoint against an active pembrolizumab control, following an already strong PFS result, is directionally coherent evidence that a dual PD-1\/VEGF mechanism can outperform standard checkpoint monotherapy in this population.<\/p>\n

Bear case:<\/strong> No hazard ratio, medians, confidence interval, maturity or updated safety data have been disclosed, and the China-only patient population may not generalize to the global HARMONi-7 population given differences in enrollment, subsequent therapy and biomarker distribution.<\/p>\n

InSilens Take<\/h4>\n

This is an important survival validation for a dual PD-1\/VEGF antibody, not yet a complete competitive dataset. The direction is positive because an active-control OS endpoint was met, but the strength of that direction remains bounded by absent effect size, maturity and safety detail. HARMONi-7 and full HARMONi-2 disclosure will determine whether the result is geographically portable and clinically practice-changing.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind Phase III study in 398 patients with PD-L1-positive advanced non-small-cell lung cancer in China. The…<\/p>\n","protected":false},"author":1,"featured_media":2885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[170,521,18,522,169],"class_list":["post-2863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-akeso","tag-ivonescimab","tag-non-small-cell-lung-cancer","tag-pembrolizumab","tag-summit-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2863"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2863\/revisions"}],"predecessor-version":[{"id":2888,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2863\/revisions\/2888"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2885"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}